Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery
- 31 January 1997
- journal article
- clinical trial
- Published by Elsevier in International Journal of Cardiology
- Vol. 58 (2) , 135-140
- https://doi.org/10.1016/s0167-5273(96)02856-2
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Chemical cardioversion of atrial fibrillation with intravenous dofetilideInternational Journal of Cardiology, 1995
- Atrial fibrillation and flutter after coronary artery bypass surgery: epidemiology, risk factors and preventive trialsInternational Journal of Cardiology, 1992
- Efficacy of intravenous propafenone in acute atrial fibrillation complicating open-heart surgeryAmerican Heart Journal, 1992
- Class III Antiarrhythmic Action and InotropyJournal of Cardiovascular Pharmacology, 1992
- Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and manXenobiotica, 1992
- Dofetilide, A Novel Class III Antiarrhythmic AgentJournal of Cardiovascular Pharmacology, 1992
- Efficacy of flecainide acetate for atrial arrhythmias following coronary artery bypass graftingThe American Journal of Cardiology, 1989
- Randomized placebo-controlled trial of propafenone for treatment of atrial tachyarrhythmias after cardiac surgeryJournal of the American College of Cardiology, 1987
- Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and digoxin in a randomised trial.Heart, 1985